IP Cases — 2026
1,011 decisions across all jurisdictions
Page 22 of 34 · 1,011 total
Cisco Systems, Inc. v.--
Cisco Systems has filed a petition for inter partes review of U.S. Patent 8,780,887, asserting that its ten claims are obvious over the Pankratov prior‑art reference. The petition seeks institution of the IPR and cancellation of the challenged claims.
Scipharm Sarl v.Assistant Controller Of Patents And Designs and Anr
Scipharm Sarl appealed the rejection of its patent application for a method enhancing engraftment of haematopoietic stem cells. The High Court allowed the appeal, permitting the appellant to amend the claims by deleting claim no.1 and retaining claims 2 to 5, and remanded the matter back to the Controller's office for further consideration.
IMI Hydronic Engineering Deutschland GmbH v.Belparts Group N.V.
IMI Hydronic Engineering Deutschland GmbH filed a revocation action against Belparts Group N.V. concerning European Patent EP3812870, to which Belparts responded with a counterclaim for infringement and an application to amend the patent. After the parties reached an out-of-court settlement, both parties applied to withdraw their respective actions. The Court granted the withdrawals, declared the proceedings closed, and entered the decision on the register without issuing a cost decision.
Krisp Technologies, Inc. v.Sanas.AI, Inc.
Krisp Technologies has filed an IPR petition challenging Sanas.ai’s U.S. Patent No. 12,125,496 covering neural‑network‑based voice enhancement. The petition asserts that all 20 claims are obvious over a combination of prior‑art references and proposes a specific construction for the term “low‑dimensional representation.”
SANOFI-AVENTIS DEUTSCHLAND GMBH, SANOFI-AVENTIS GROUPE S.A., SANOFI WINTHROP INDUSTRIE S.A., and Regeneron Pharmaceuticals Inc. v.AMGEN, INC
This decision concerns an application by Sanofi and Regeneron to withdraw their application for rehearing filed against the Court of Appeal's 25 November 2025 decision, which had set aside the Central Division Munich's revocation of EP 3 666 797 and rejected the revocation request. Amgen consented to the withdrawal and indicated no decision on costs was necessary. The Court of Appeal permitted the withdrawal, declared the proceedings closed, and rejected the request for reimbursement of court fees because only one fee had been paid when two were due.
F. Hoffmann-La Roche AG a.o. v.A. Menarini Diagnostics S.r.l. a.o.
This case concerned a patent infringement action filed by F. Hoffmann-La Roche AG and Roche Diabetes Care GmbH against A. Menarini Diagnostics entities regarding European Patent EP 1 962 668. Before the written proceedings were concluded, the plaintiffs withdrew the action and requested a 50% reimbursement of court fees, with the defendants consenting to the withdrawal. The parties had reached an out-of-court settlement under which each side bears its own costs, and the court allowed the withdrawal, declared the proceedings terminated, and ordered partial reimbursement of court fees.
Par Health, Inc. v.InfoRLife, S.A.
Par Health petitions the PTAB to institute a post‑grant review of U.S. Patent 12,370,153 covering ready‑to‑use ketamine infusion formulations. The petition asserts anticipation by a Biomed data sheet and obviousness over Biomed combined with standard pharmaceutical references and commercial infusion bag literature.
Bardana Super Hi-Tech Agro Tonic Pvt v.Amcons Ipl (Agro Industrial Expansion) Pvt Ltd and Others
The plaintiff filed a commercial suit seeking permanent injunctions against the defendants for dishonestly adopting and using the impugned mark "SUPER AGRO-TECH" along with deceptively similar packaging and trade dress in relation to agricultural goods. The applicant sought dispensation of pre-institution mediation, arguing that urgent interim relief was necessary due to immediate market confusion and injury.
Applicant *** v.Amycel, LLC
The Court of Appeal of the Unified Patent Court declared a second application for suspensive effect (R. 223 RoP) inadmissible. The Applicant, who was the defendant in infringement proceedings concerning EP 1 993 350, had already filed a first application for suspensive effect that was rejected on 16 January 2026. The second application, filed on 20 February 2026, raised arguments identical or very similar to those in the first application, and the court held that the Applicant failed to demonstrate that the new submissions could not reasonably have been made in the previous application.
Amgen N.V., Amgen S.R.L, Amgen GmbH, Amgen B.V., Amgen S.A.S., Amgen Inc., Amgen Europe B.V. v.Regeneron Pharmaceuticals Inc. and Sanofi Biotechnology SAS
This appeal concerned EP 3 536 712, where Amgen had appealed a decision of the Düsseldorf Local Division dismissing its counterclaim for revocation. After the written procedure was closed and an oral hearing was scheduled, the parties reached an out-of-court settlement, and Amgen applied to withdraw the appeal pursuant to R. 265 RoP, with Sanofi and Regeneron consenting. The Court of Appeal permitted the withdrawal and declared the proceedings closed, but dismissed Amgen's request for reimbursement of court fees because the withdrawal occurred after the closure of the written procedure, falling outside the scope of R. 370.9(b) RoP.
ALPINA Coffee Systems GmbH v.CUP&CINO Kaffeesystem-Vertrieb GmbH & Co. KG
This is an order from the Court of Appeal concerning ALPINA Coffee Systems GmbH's request for suspensive effect (stay of enforcement) of its appeal against a decision of the Local Chamber Düsseldorf. The underlying decision of March 18, 2026 had largely found that ALPINA's milk frother 'ALPINA Latte Perfetto Duo' infringed European Patent EP 3 398 487, while ALPINA's counterclaim for revocation was unsuccessful. ALPINA filed its appeal on March 19, 2026, and sought suspensive effect at least until it becomes clear whether and to what extent CUP&CINO will seek enforcement in parallel proceedings concerning related European patents.
Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc. v.Amgen N.V., Amgen S.R.L, Amgen GmbH, Amgen B.V., Amgen S.A.S., Amgen Inc., Amgen Europe B.V.
This appeal concerned EP 3 536 712, where Sanofi and Regeneron appealed a decision of the Düsseldorf Local Division dated 13 May 2025 that dismissed their infringement action and ordered them to bear the costs. After the written procedure was closed, the appellants applied to withdraw the appeal pursuant to R. 265 RoP, indicating the parties had reached an agreement, and sought reimbursement of 50% of court fees. The Court of Appeal permitted the withdrawal, declared no cost decision necessary, but dismissed the request for reimbursement of court fees because the withdrawal occurred after the closure of the written procedure.
REEL International (claimant) v.Fives ECL (defendant)
1 Ordonnance de procédure du Tribunal de première instance de la Juridiction unifiée du brevet, Division centrale (Section Munich) rendue le 24 mars 2026 EN-TETE Le défaut d’intérêt à agir et l’autorité de la chose jugée, que le défendeur à une action invoque pour dénier à
BTL Medizintechnik GmbH v.Lexter Microelectronic Engineering Systems S.L.
This procedural order concerns the reimbursement of court fees following the withdrawal of a patent infringement action. The Claimant, BTL Medizintechnik GmbH, had filed an infringement action regarding EP 4 426 414 against the Defendant, Lexter Microelectronic Engineering Systems S.L., and subsequently withdrew the action. The Court ordered the Registrar to reimburse the Claimant 60% of the court fees (6,600 EUR) pursuant to Rule 370.9 RoP (2025), as the action was terminated before the closure of the written procedure.
Altria Client Services LLC v.--
Altria Client Services LLC petitions the PTAB to cancel a design patent for a dog‑toy set that mimics Marlboro cigarette packaging, citing a 1959 Life Magazine ad and a 1976 trademark registration as prior art.
Chugai Seiyaku Kabushiki Kaisha & Anr. v.Basil Drugs And Pharmaceuticals Private Limited
The plaintiffs, Chugai Seiyaku Kabushiki Kaisha & Anr., filed a commercial suit alleging infringement of their patent (IN 294424) related to the compound Alectinib. The court addressed several interlocutory applications and subsequently registered the plaint as a suit, while also granting an interim injunction restraining the defendant from manufacturing or dealing in infringing products.
Gsp Crop Science Private Limited v.Fmc Agro Singapore Pte Ltd & Ors.
The court addressed arguments regarding the maintainability and survival of a revocation petition under Section 64 of the Patents Act, 1970. The order noted that a Division Bench had held that such a petition remains maintainable even after patent expiry or when an invalidity defence is raised in suit.
Msn Laboratories Pvt. Ltd v.The Controller Of Patents & Anr.
The petitioner sought orders regarding the maintainability and survival of a revocation petition under Section 64 of the Patents Act, 1970. The court noted that the issue had been addressed by a Division Bench judgment in another appeal (Boehringer Ingelheim Pharma GMBH vs. The Controller of Patents & Anr).
Novo Nordisk A/S & Anr v.Dr. Reddy's Laboratories Limited
Novo Nordisk filed a commercial suit seeking an interim injunction against Dr. Reddy's Laboratories concerning their patented composition involving semaglutide. The court heard arguments, noted affidavits from both sides, and allowed procedural applications while directing the parties to proceed with pleadings.
Versah LLC v.Argimiro Antonio Hernandez Suarez
Versah LLC filed a patent infringement action against Argimiro Antonio Hernandez Suarez concerning European Patent EP 2 919 672 B1. Before the written proceedings were concluded, the plaintiff withdrew the lawsuit and requested a partial refund of court fees. The defendant consented to both the withdrawal and the fee refund, and the court allowed the withdrawal, declared the proceedings terminated, and ordered a 60% refund of the court fees paid by the plaintiff.
VALEO SYSTEMES D’ESSUYAGE v.ROBERT BOSCH DOO, ROBERT BOSCH FRANCE S.A.S., ROBERT BOSCH GmbH, ROBERT BOSCH S.A., ROBERT BOSCH PRODUKTIE S.A., BOSCH AUTOMOTIVE PRODUCTS (CHANGSHA) CO., LTD.
1 Division Locale de Paris UPC_CFI_1963/2025 Ordonnance de procédure du Tribunal de première instance de la Juridiction unifiée du brevet, rendue le 23 mars 2026 (R333 RdP révision d’une ordonnance) ENTETE La condition fixée par l’article 33.1(b) AJUB relative au lien commercial entre le
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck challenges Halozyme’s PH20 enzyme patent, asserting that a 2013 publication anticipates all 18 claims and that the specification lacks written description and enablement. The petition seeks inter partes review under § 102 and § 112(a).
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC has filed an IPR petition challenging Halozyme’s U.S. Patent 11,041,149 covering engineered PH20 hyaluronidase proteins. The petition alleges lack of written description, enablement, and anticipates all claims under prior art US‑275.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed an IPR petition challenging Halozyme’s ’656 patent covering engineered PH20 hyaluronidase proteins. The petition asserts lack of written description and enablement and that US‑275 anticipates all claims.
Amazon.com Services LLC et al. v.Smart Speaker LLC
Amazon has filed an IPR petition challenging 27 claims of Smart Speaker’s ’720 patent, asserting obviousness over a suite of prior‑art references covering microphones, WLAN, speakers, and lighting. The petition highlights a deficient examiner search and seeks cancellation of all challenged claims.
Novartis Ag v.Bdr Pharmaceuticals International Private Limited
This order addresses several interlocutory applications filed by Novartis Ag against Bdr Pharmaceuticals International. The court granted exemptions from pre-institution mediation and allowed additional documents, while also considering arguments regarding the scope of the defendants' license under the Patents Act.
Wirtgen Gmbh v.Controller General Of Patents, Designs and Trademarks and Ors
Wirtgen Gmbh appealed a rejection order issued by the Controller General of Patents, Designs and Trademarks. The rejection was based on lack of inventive step and insufficient claim definition under the Patents Act. The High Court found that the impugned order suffered from analytical and procedural deficiencies.
Daewoong Pharmaceutical Co. Ltd. v.Controller General Of Patents Designs and Trademarks
Daewoong Pharmaceutical appealed the rejection of its patent application (No. 201817048074) by the Controller General, which was based on non-patentability under Section 3(d). The appeal challenged the decision to reject the application despite submissions regarding improved therapeutic efficacy and stability data.
Sanofi - Aventis v.Controller General Of Patents, Designs and Trademarks And Anr.
Sanofi - Aventis appealed an order from the Assistant Controller of Patents & Designs. The appellant argued that the impugned order was perverse because it failed to adequately address arguments concerning lack of inventive steps and should have been based on Section 3(d) of the Patents Act, 1970.
HyGear B.V., SYPOX GmbH - Josef Kerner Energiewirtschafts GmbH - Technical University of Munich v.Topsoe A/S
This order concerns HyGear B.V.'s application to change the language of proceedings from German to English in a case involving European patent EP3802413 relating to hydrogen production by steam methane reforming. The main proceedings were initiated by Topsoe A/S against HyGear B.V., SYPOX GmbH, Josef Kerner Energiewirtschafts GmbH, and the Technical University of Munich. The President of the Court of First Instance was asked to decide on the language change request pursuant to Rule 323 of the Rules of Procedure, with most parties consenting to the change except the Technical University of Munich.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.